BRIEF-Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial

June 4 (Reuters) - Spectral Medical Inc EDT.TO:

  • SPECTRAL MEDICAL AND VANTIVE ANNOUNCE TOPLINE 12 MONTH FOLLOW-UP RESULTS FROM SPECTRAL’S TIGRIS TRIAL

  • SPECTRAL MEDICAL - 100% FOLLOW-UP ACHIEVED FOR ALL 157 TIGRIS TRIAL PATIENTS

  • SPECTRAL MEDICAL - 12-MONTH MORTALITY 52.8% WITH PMX VERSUS 66.7% WITH STANDARD OF CARE IN TIGRIS TRIAL

  • SPECTRAL MEDICAL - ABSOLUTE RISK REDUCTION AT 12 MONTHS 13.9%, NUMBER NEEDED TO TREAT 7.2

  • SPECTRAL MEDICAL - 95.9% PROBABILITY OF BENEFIT FOR PMX AT 12 MONTHS BASED ON TIGRIS DATA

Source text: ID:nGNX23Gq0Y

Further company coverage: EDT.TO


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.